Triterpene saponins, methods of synthesis and uses thereof
US12227535B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 19, 2022 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | Sep 19, 2042 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.